May 4, 2020 / 1:02 PM / a month ago

BRIEF-KemPharm - NDA Filing For Potential New ADHD Treatment Accepted By FDA

May 4 (Reuters) - KemPharm Inc:

* NDA FILING FOR POTENTIAL NEW ADHD TREATMENT, KP415, ACCEPTED BY FDA; KEMPHARM ELIGIBLE TO RECEIVE $5 MILLION MILESTONE PAYMENT FROM GURNET POINT CAPITAL

* KEMPHARM INC - COULD HAVE A POTENTIAL ACTION (PDUFA) DATE IN MARCH 2021 FOR KP415

* KEMPHARM INC - CORIUM, INC TO LEAD ALL COMMERCIALIZATION ACTIVITIES FOR KP415, IF APPROVED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below